- 1 -

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

China Bio-Med Regeneration Technology Limited

中國生物醫學再生科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8158) POLL RESULT OF THE EXTRAORDINARY GENERAL MEETING HELD ON 6 FEBRUARY 2015

Reference is made to the circular of China Bio-Med Regeneration Technology Limited (the
"Company") dated 20 January 2015 (the "Circular") and the notice of EGM dated 20
January 2015. Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the Circular.

POLL RESULT OF THE EGM

The Board is pleased to announce that the ordinary resolution set out in the notice of EGM
dated 20 January 2015 was duly passed by the Independent Shareholders at the EGM held on
6 February 2015 by way of poll.
As at the date of the EGM, the total number of issued Shares was 11,912,880,000 Shares. All Favour is indirectly owned as to 60% by Mr. Dai Yumin, an executive Director, through his shareholding interests in Forerunner Technology Limited and Honour Top Holdings Limited, and is also a substantial shareholder of the Company which is interested in approximately 14.15% of the Shares in issue. Accordingly, All Favour and its associates have abstained from voting at the EGM in respect of the resolution approving the Placing Agreement and the transactions contemplated thereunder, and the Specific Mandate. As a result of the abstention of All Favour and its associates, the total number of Shares
entitling the holders to attend and vote for or against the proposed resolution in respect of the

1

Placing Agreement and the transactions contemplated thereunder, and the Specific Mandate at the EGM was 10,227,559,681 Shares, representing approximately 85.85% of the total issued share capital of the Company as at the date of the EGM. None of the Shares would entitle the holder thereof to attend and vote only against the proposed resolution. None of the Shareholders has stated any intention in the Circular to vote against the proposed resolution at the EGM.
Save as disclosed above, there were no restriction on any Shareholder to cast votes in respect of the resolution proposed at the EGM.
The Company's Hong Kong branch share registrar, Union Registrars Limited, was appointed
as the scrutineer for the purpose of vote taking at the EGM. The poll result in respect of the resolution proposed at the EGM are as follows:

Ordinary Resolution

Number of votes (%)

Ordinary Resolution

For

Against

1. (a) the Placing Agreement dated 10

November 2014 entered into between the Company and Sheng Yuan Securities Limited as placing agent in relation to the placing of up to 6,000,000,000

Placing Shares on a best-effort basis at the Placing Price of HK$0.25 per Placing Share, and the grant of Options at an aggregate nominal consideration of HK$1 payable by each Placee carrying rights to subscribe for up to 900,000,000

Option Shares, representing 15% of the number of Placing Shares subscribed for by the Placees, on the terms set out in the terms and conditions of the Options at the initial Exercise Price of HK$0.25 per Option Share (subject to adjustments) (a copy of the Placing Agreement has been produced to this meeting marked "A" and signed by the chairman of this meeting for the purpose of identification) and the transactions contemplated thereunder be and are hereby approved, confirmed and ratified;

2,670,809,000

(98.67%)

36,010,000

(1.33%)

2

(b) the Directors be and are hereby granted the Specific Mandate to (i) issue and allot 3,400,000,000 and 2,600,000,000
Placing Shares to All Favour and Independent Placees respectively, for the Relevant Period; and (ii) grant the Options to the Placees and issue and allot
510,000,000 and 390,000,000 Option Shares to All Favour and Independent Placees, respectively, upon exercise of the Options in accordance with the terms
thereof, subject only to the Placing
Agreement becoming unconditional in accordance with the terms thereof. The Specific Mandate is in addition to, and shall not prejudice nor revoke any existing or such other general or special mandates which may from time to time be granted to the Directors prior to the passing of this resolution. For the purpose of this resolution, "Relevant Period" means the period starting from the date of passing of this resolution up to the expiration of the 4-week period following the date of passing of this resolution;
(c) the issue and allotment of 3,400,000,000
Placing Shares and 510,000,000 Option
Shares to All Favour and 2,600,000,000
Placing Shares and 390,000,000 Option Shares to Independent Placees, credited as fully paid, at the Placing Price per Placing Share and at the Exercise Price per Option Share (subject to adjustments) (as the case may be) pursuant to the Specific Mandate be and is hereby approved; and
(d) the Directors be and are hereby authorised to do all other acts and things and execute all documents which he/she/they consider(s) necessary or expedient for the implementation of and giving effect to the Placing Agreement and the transactions contemplated thereunder.

As more than 50% of the votes were cast in favour of above resolution, the resolution was
duly passed as ordinary resolution of the Company.

3

By order of the Board

China Bio-Med Regeneration Technology Limited Dai Yumin

Executive Director

Hong Kong, 6 February 2015

As at the date of this announcement, the executive Directors are Mr. Dai Yumin and Ms. Wang Yurong; the non-executive Directors are Mr. Wong Sai Hung, Professor Deng Shaoping, Mr. Cao Fushun, Mr. Yang Zhengguo, Mr. Ma Long and Mr. Wang Jianjun; and the independent non-executive Directors are Mr. Lui Tin Nang, Mr. Chan Wing Hang, Mr. Pang Chung Fai Benny and Mr. Chan Bing Woon, SBS, JP.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Company Announcement" page of the GEM website at www.hkgem.com for at least seven days from the date of the publication and will be published on the website of the Company at www.bmregeneration.com.

4

distributed by